Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding its financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about the credibility of Tempus AI's joint venture with SoftBank Group Corporation, suggesting it created an appearance of "round-tripping" capital to inflate revenue [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is alleged to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca PLC reportedly reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement, raising further concerns about the company's financial health [3]. - These issues collectively indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 2: Impact of Research Report - On May 28, 2025, a research report from Spruce Point Capital Management raised numerous red flags regarding Tempus AI's management, operations, and financial reporting, resulting in a stock price drop of over 19% [4]. Group 3: Class Action Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Tempus AI common stock during the specified Class Period to seek appointment as lead plaintiff in the class action lawsuit [5]. - The lead plaintiff is typically the investor with the greatest financial interest in the case and acts on behalf of all other class members [5]. - Investors can choose their own law firm to represent them in the lawsuit, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5].

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding its financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - It is alleged that the credibility of Tempus AI's joint venture with SoftBank Group was compromised, creating an appearance of "round-tripping" capital to generate revenue [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca's financial commitments to Tempus AI were reportedly reduced through a questionable "pass-through payment" arrangement, raising concerns about the company's revenue prospects [3]. - These issues collectively indicate weaknesses in Tempus AI's core operations and revenue potential [3]. Group 2: Impact of Research Report - On May 28, 2025, a research report from Spruce Point Capital Management raised significant concerns regarding Tempus AI's management and financial reporting, resulting in a stock price drop of over 19% [4]. Group 3: Class Action Process - Investors who purchased Tempus AI common stock during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. - The lead plaintiff has the authority to select a law firm for litigation and does not need to serve as lead plaintiff to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].